[HTML][HTML] Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings
TI Verhoef, WK Redekop, F Hasrat, A de Boer… - American Journal of …, 2014 - Springer
Objectives Our objectives were to investigate the cost effectiveness of apixaban,
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings
T Verhoef, K Redekop, F Hasrat, A de Boer… - American Journal of …, 2014 - repub.eur.nl
Objectives: Our objectives were to investigate the cost effectiveness of apixaban,
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
[PDF][PDF] Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings
TI Verhoef, WK Redekop, F Hasrat, A de Boer… - Am J Cardiovasc …, 2014 - pure.eur.nl
Objectives Our objectives were to investigate the cost effectiveness of apixaban,
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
[PDF][PDF] Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings
TI Verhoef, WK Redekop, F Hasrat, A de Boer… - Am J Cardiovasc …, 2014 - Citeseer
Objectives Our objectives were to investigate the cost effectiveness of apixaban,
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings
TI Verhoef, WK Redekop, F Hasrat… - … devices, and other …, 2014 - pubmed.ncbi.nlm.nih.gov
Objectives Our objectives were to investigate the cost effectiveness of apixaban,
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings
TI Verhoef, WK Redekop… - American …, 2014 - researchinformation.amsterdamumc …
Objectives Our objectives were to investigate the cost effectiveness of apixaban,
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings.
T Verhoef, W Redekop, F Hasrat… - American Journal of …, 2014 - search.ebscohost.com
Objectives: Our objectives were to investigate the cost effectiveness of apixaban,
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings
TI Verhoef, WK Redekop, F Hasrat, A Boer… - American Journal of …, 2014 - infona.pl
Objectives Our objectives were to investigate the cost effectiveness of apixaban,
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
[HTML][HTML] Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings
TI Verhoef, WK Redekop, F Hasrat… - American Journal of …, 2014 - ncbi.nlm.nih.gov
Objectives Our objectives were to investigate the cost effectiveness of apixaban,
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
[PDF][PDF] Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings
TI Verhoef, WK Redekop, F Hasrat, A de Boer… - 2014 - researchgate.net
Objectives Our objectives were to investigate the cost effectiveness of apixaban,
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …